Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Juan Antonio García-Carmona & Sofia Pappa. (2023) Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal. Drug, Healthcare and Patient Safety 15, pages 113-123.
Read now
Read now
S Kor Spoelstra, Jojanneke Bruins, Leonie Bais, Paul Seerden, Stynke Castelein & Henderikus Knegtering. (2022) One-Month versus Three-Month Formulation of Paliperidone Palmitate Treatment in Psychotic Disorders: Patients’, Relatives’, and Mental Health Professionals’ Perspectives. Patient Preference and Adherence 16, pages 615-624.
Read now
Read now
Antoine C El Khoury, Charmi Patel, Panagiotis Mavros, Ahong Huang, Li Wang & Richa Bashyal. (2021) Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia. Neuropsychiatric Disease and Treatment 17, pages 3159-3170.
Read now
Read now
Alicia Lopez & Jose Rey. (2019) Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice. Neuropsychiatric Disease and Treatment 15, pages 449-456.
Read now
Read now
Junwen Zhou, Aurélie Millier, Clément François, Samuel Aballéa & Mondher Toumi. (2019) Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results. Journal of Market Access & Health Policy 7:1.
Read now
Read now
Miquel Bioque & Miquel Bernardo. (2018) The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy 19:14, pages 1623-1629.
Read now
Read now
Claudio Brasso, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni & Paola Rocca. (2017) Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia. Neuropsychiatric Disease and Treatment 13, pages 2767-2779.
Read now
Read now
Articles from other publishers (9)
Rui Luo, He Lu & Hengfen Li. (2023) Cost-utility analysis of using paliperidone palmitate in schizophrenia in China. Frontiers in Pharmacology 14.
Crossref
Crossref
Luis Gutiérrez‐Rojas, Sergio Sánchez-Alonso, Marta García Dorado & Paola M. López Rengel. (2022) Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain. CNS Drugs 36:5, pages 517-527.
Crossref
Crossref
Richard Dodel, Christopher Kruse, Annette Conrads-Frank & Uwe Siebert. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
101
234
.
Luying Wang, Fenghao Shi, Xin Guan, He Xu, Jing Liu & Hongchao Li. (2021) A Systematic Review of Methods and Study Quality of Economic Evaluations for the Treatment of Schizophrenia. Frontiers in Public Health 9.
Crossref
Crossref
Katalin Pungor, Vasilis P. Bozikas, Robin Emsley, Pierre-Michel Llorca, Srihari Gopal, Maju Mathews, Annette Wooller & Paul Bergmans. (2020) Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes. Therapeutic Advances in Psychopharmacology 10, pages 204512532098150.
Crossref
Crossref
Richard Dodel, Christopher Kruse, Annette Conrads-Frank & Uwe Siebert. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
135
.
Charmi Patel, Antoine El Khoury, Ahong Huang, Li Wang, Onur Baser & Kruti Joshi. (2019) Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis. Advances in Therapy 36:10, pages 2941-2953.
Crossref
Crossref
Jonathan K. Lai & Howard C. Margolese. (2019) A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic. Schizophrenia Research 204, pages 443-444.
Crossref
Crossref
Maral DerSarkissian, Patrick Lefebvre, Kruti Joshi, Brianne Brown, Marie-Hélène Lafeuille, Rachel H. Bhak, Michael Hellstern, Priyanka Bobbili, Brian Shiner, Antoine C. El Khoury & Yinong Young-Xu. (2018) Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans. Clinical Therapeutics 40:9, pages 1496-1508.
Crossref
Crossref